Related Experiment Videos
Relationship between CaMBr1 expression and tumor progression in small cell lung carcinomas
S Martignone1, A V Bedini, A Ciavolella
1Division of Experimental Oncology E, Istituto Nazionale Tumori, Milan, Italy.
Tumori
|August 31, 1989
Summary
This study found that small cell lung carcinoma (SCLC) tumors expressing the CaMBr1 marker are more common in metastases and associated with shorter patient survival. This suggests CaMBr1 may indicate more aggressive lung cancer.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Antigenic phenotype can influence tumor progression and patient outcomes.
- Small cell lung carcinoma (SCLC) is an aggressive form of lung cancer with variable metastatic potential.
Purpose of the Study:
- To investigate the relationship between antigenic phenotype, specifically the expression of the CaMBr1 marker, and tumor progression in SCLC.
- To determine if CaMBr1 expression correlates with survival in SCLC patients.
Main Methods:
- Immunofluorescence and immunoperoxidase techniques were used to test 63 SCLC biopsies (primary and metastatic) with the anti-carcinoma monoclonal antibody MBr1.
- Life table analysis was performed to assess the association between CaMBr1 expression and overall survival.
Main Results:
- Metastatic SCLC lesions showed higher MBr1 reactivity (75-89%) compared to primary tumors (57%).
- A significant inverse association was found between CaMBr1 expression and overall survival (p < 0.01).
- Patients with MBr1-positive tumors had shorter survival times, even in early-stage disease (p < 0.05).
Conclusions:
- CaMBr1 expression is associated with increased metastatic potential in SCLC.
- The CaMBr1 marker may serve as a prognostic indicator for shorter survival in SCLC patients.
- MBr1-positive tumors might exhibit greater aggressiveness or resistance to therapy.